Ochi Yukio, Hamazu Masanari, Kajita Yoshihiro, Hachiya Takashi, Kunimatsu Mitoshi, Sato Takaaki, Nagata Atsuo
Research Institute for Production Development, Shimogamo, Kyoto, Japan.
Endocr J. 2008 Mar;55(1):105-11. doi: 10.1507/endocrj.k07e-015. Epub 2008 Jan 17.
TSH receptor (R) binding and cAMP production by bovine (b) TSH-bound to a monoclonal antibody (MoAb) or polyclonal antibody (Ab) to bTSH were examined, using TSH receptor (R) coating tube and porcine thyroid cells. (125) I-bTSH bound-to MoAbs to bTSH(alpha) or discontinuous type MoAb showed TSHR binding (10%) similar to intact (125) I-bTSH. TSHR binding was completely decreased (<2%) when (125) I-bTSH was bound by polyclonal Abs to bTSH(alpha) in Graves' patient or rabbit polyclonal Abs to bTSH. When either of the two MoAb (No. 1 and 2) to bTSH(beta) was bound to (125) I-bTSH, TSHR binding was 4 times higher (40%) compared to intact (125) I-bTSH. Binding of another MoAb (No. 3) caused no increased binding. TSHR binding of intact (125) I-bTSH was decreased from 10% to 2% by excess amounts of bTSH. Binding of (125) I-bTSH bound to MoAb to bTSH(beta) (No. 1 and 2) decreased from 40% to 30% by excess amounts of bTSH. When (125) I-bTSH bound-Fab of MoAb was used, the binding was reduced from 30 to 10% (No. 1) and from 25 to 6% (No. 2), respectively. In contrast, cAMP production by bTSH was decreased by pre-binding of all MoAbs and polyclonal Abs. Binding of (125) I-MoAb to bTSH (beta) to a synthetic peptide array of bTSH (beta) sequence was examined by the radioautography. The epitope of MoAb to bTSH(beta) was suggested to be LPK (beta 42-44) for No. 1, KLF (beta 39-41) for No. 2 and PKYA (beta 43-46) for No. 3, respectively, although the existence of discontinuous epitope could not be ruled out. The increased TSHR binding and the decreased cAMP production by bTSH bound to MoAbs may be due to the conformational change of TSH molecule or TSHR by binding of both bTSH and MoAb.
利用促甲状腺激素(TSH)受体包被管和猪甲状腺细胞,检测了与抗牛促甲状腺激素(bTSH)的单克隆抗体(MoAb)或多克隆抗体(Ab)结合的牛促甲状腺激素(bTSH)的TSH受体(R)结合及环磷酸腺苷(cAMP)生成情况。与抗bTSH(α)的MoAb或不连续型MoAb结合的(125)I-bTSH显示出与完整的(125)I-bTSH相似的TSHR结合(10%)。当(125)I-bTSH被格雷夫斯病患者的抗bTSH(α)多克隆抗体或兔抗bTSH多克隆抗体结合时,TSHR结合完全降低(<2%)。当两种抗bTSH(β)的MoAb(1号和2号)中的任何一种与(125)I-bTSH结合时,TSHR结合比完整的(125)I-bTSH高4倍(40%)。另一种MoAb(3号)的结合未导致结合增加。过量的bTSH使完整的(125)I-bTSH的TSHR结合从10%降至2%。与抗bTSH(β)的MoAb(1号和2号)结合的(125)I-bTSH的结合因过量的bTSH从40%降至30%。当使用与MoAb结合的(125)I-bTSH的Fab时,结合分别从30%降至10%(1号)和从25%降至6%(2号)。相反,所有MoAb和多克隆抗体的预结合均降低了bTSH诱导的cAMP生成。通过放射自显影检测了与bTSH(β)序列的合成肽阵列结合的(125)I-MoAb抗bTSH(β)。尽管不能排除不连续表位的存在,但对于1号MoAb,抗bTSH(β)的表位推测为KLF(β39 - 41),对于2号MoAb为PKYA(β43 - 46),对于3号MoAb为PKYA(β43 - 46)。与MoAb结合的bTSH导致的TSHR结合增加和cAMP生成减少可能是由于bTSH和MoAb结合导致TSH分子或TSHR的构象变化。